Hubbard, Ohio-based NanoLogix is collaborating with University of Texas Health Science Center on a multi-well, microplate reader variant of the company’s BioNanoFilter (BNF) diagnostics for use in large volume laboratory environments.

Early analysis of the multi-well plates shows exceptionally fast live-threat results similar to the company’s standard BNF technology. The technology will be shown off at the General Meeting of the American Society for Microbiology in San Francisco later this week.

Research using NanoLogix technology from a recently completed clinical study will also be presented at the ASM meeting. The research focused on detection, identification, and determination of antibiotic sensitivity of Group B Streptococcus during pregnancy. Data showed NanoLogix diagnostics consistently provided results in a 4 to 6 hour window, dramatically shorter than standard culturing times of 48 to 72 hours.

“These are exciting times for NanoLogix,” said CEO Bret Barnhizer. “Our technology has the potential to dramatically affect the course of human health and events over the past eight months have greatly enhanced our position for the future.”

The company’s bacteria and protozoa detection technology portfolio also received a boost recently. A third-party research lab found that live-threat Tuberculosis was detected with NanoLogix technology in 4 to 5 days, as opposed to 21 to 84 days with standard culture. TB was also detected and identified with the company’s BNF technology in less than two hours. Peer-reviewed publication and FDA submittal are in process for results from both BNP and BNF Tuberculosis research.